Iko kusanganiswa kwema monoclonal antibodies maviri ekurapa lymphoma ndeye 50% inoshanda

Share This Post

Zvinoenderana neakawanda-center kiriniki kuyedza inotungamirwa nevaongorori paStanford University Chikoro cheMishonga, mhando nyowani yekudzivirira muviri inoita kunge yakachengeteka kuvarwere vane gomarara reropa inonzi non-Hodgkin's lymphoma.

The therapy combines experimental antibodies developed by researchers at Stanford University and commercially available anti-cancer antibodies to rituximab. It referred Hu5F9-G4 experimental protein antibody blockade of CD47 , of CD47 suppressed immune attack against cancer cells. The combination of two antibodies is used to treat people with two types of kwete-Hodgkin's lymphoma: diffuse large B- cell lymphoma and follicular lymphoma.

Muna 2010, vaongorori vakatungamirwa naIrving Weissman, MD, director weStanford Stem Cell Biology uye Regenerative Medicine Institute, vakaratidza kuti angangoita ese maseru egomarara akafukidzwa neprotein inonzi CD47, iyo inogona kutamba "usandidye" Chiratidzo kune macrophages.

Weissman nevamwe vaaishanda navo vakazogadzira antibody inonzi Hu5F9-G4 inovhara mapuroteni eCD47 uye inokurudzira macrophages kuvhara maseru egomarara. Rituximab inonzi antibody yakaratidzwa kuwedzera iyo yakanaka "ndidye ini" chiratidzo. Iko kusanganiswa kwe rituximab neHu5F-G4 kwakamboratidzwa kuve kunoshanda kurwisa gomarara remunhu mumhando dzemhuka, asi iyi ndiyo yekutanga kuburitswa mhedzisiro yekiriniki miedzo yekurapa muvanhu.

Pakati pevarwere makumi maviri nevaviri vaitora muyedzo, varwere gumi nemumwe vaive vaderedza kenza yekiriniki, uye varwere vasere vakabvisa zviratidzo zvese zvegomarara. Vamwe varwere vatatu mukutongwa havana kupindura kurapwa uye vakafa nekuda kwekuwedzera kwechirwere. Vatsvakurudzi vakaona kuti vatori vechikamu vaive nemhedzisiro diki.

Dr. Saul A. Rosenberg , a lymphoma professor , said that such a potential new immunotherapy is very exciting. This is the first time that an antibody that can activate macrophages to fight cancer is used, and it seems to be safe for use in humans.

https://medicalxpress.com/news/2018-10-anti-cd47-cancer-therapy-safe-small.html

Subscribe To Newsletter Vedu

Wana zvigadziriso uye usambopotsa blog kubva kuCancerfax

Zvimwe Kuti Uongorore

Kurapa Kwemasero eCAR T kunoitwa nevanhu: Kubudirira Uye Zvinetso
CAR T-Cell kurapa

Kurapa Kwemasero eCAR T: Kubudirira uye Zvinetso

Human-based CAR T-cell therapy inosandura kurapwa kwegomarara nekugadzirisa magene masero emuviri emurwere kuti anange nekuparadza maseru egomarara. Nekushandisa simba rekudzivirira kwemuviri, marapirwo aya anopa marapiro ane simba uye emunhu ane mukana wekuregererwa kwenguva refu mumhando dzakasiyana dzegomarara.

Kunzwisisa Cytokine Release Syndrome: Zvinokonzera, Zviratidzo, uye Kurapa
CAR T-Cell kurapa

Kunzwisisa Cytokine Release Syndrome: Zvinokonzera, Zviratidzo, uye Kurapa

Cytokine Release Syndrome (CRS) is immune system reaction inowanzo kukonzerwa nemamwe marapirwo senge immunotherapy kana CAR-T cell therapy. Zvinosanganisira kuburitswa kwakanyanya kwemacytokines, zvichikonzera zviratidzo kubva pafivha uye kuneta kusvika kune zvinogona kuuraya hupenyu sekukuvadzwa kwenhengo. Kutungamira kunoda kunyatsotarisisa uye nzira dzekupindira.

Kuda rubatsiro? Chikwata chedu chakagadzirira kukubatsira.

Tinoshuvira kupora nekukurumidza kwemudiwa wako uye padyo neuyo.

Kutanga kutaura
Tiri paIndaneti! Taura Nesu!
Skena kodhi
Mhoro,

Kugamuchirwa kuCancerFax!

CancerFax ipuratifomu yekupayona yakatsaurirwa kubatanidza vanhu vakatarisana negomarara repamberi nekurapa kwesero seCAR T-Cell therapy, TIL kurapwa, uye miedzo yekiriniki pasi rese.

Tizivise zvatinogona kukuitira.

1) Kurapwa kwegomarara kunze kwenyika?
2) CAR T-Cell therapy
3) Mushonga wegomarara
4) Online vhidhiyo kubvunza
5) Proton kurapwa